The STING pathway plays a dual role in cancer. On one hand, it can promote anti-tumor immunity by enhancing the activation of dendritic cells and the subsequent priming of T cells. This makes the pathway a target for cancer immunotherapy. On the other hand, chronic activation of the STING pathway can lead to a pro-tumorigenic inflammatory environment. This dual nature of the STING pathway makes it a complex but promising target in cancer treatment.
